Introduction
Arrhythmogenic cardiomyopathy is a term recently coined to include several clinically heterogeneous disorders that affect both the structure and function of the heart, the most severe outcome being sudden cardiac death (SCD) in young adults due to ventricular tachyarrhythmias. 1 Arrhythmogenic right ventricular cardiomyopathy [ARVC (MIM 107970)] is considered an † These authors contributed equally to this paper.
arrhythmogenic cardiomyopathy, and is a cause of early SCD. 2 Although 12 autosomal dominant ARVC loci (ARVC1-12) have been mapped and eight genes identified, 3 -5 the underlying genetic aetiology is known in only 30 -50% of ARVC cases. Identifying at-risk individuals pre-symptomatically is a problem as affected family members are often unavailable for clinical or genetic screening due to SCD in the concealed phase of the disease and although family history is helpful, it has restricted utility to define the absolute risk, and is problematic in small families. Recurrent mutations (i.e. the exact same mutation observed in two or more unrelated patients) are either the result of repeated de novo events (usually in the context of 'mutational hotspots' in the genome) or amplification in a population through vertical transmission from a common ancestor, known as a founder effect. The most recently discovered ARVC gene (TMEM43) 6 was identified on the basis of linkage to chromosome 3p25 and a recurrent missense mutation (c.1073C.T: p.S358L) identified exclusively in patients across 15 unrelated ARVC families from the island of Newfoundland, a Canadian founder population of 510 000 people of English and Irish extraction. 7 This strong founder effect was instrumental in pinpointing a missense mutation as causative, given that TMEM43 was previously unassociated with human disease and there was no available functional assay. The disease haplotype was reconstructed by genotyping polymorphic markers spanning the critical region on 3p25 in patients, which identified a 2.36 Mb shared ancestral haplotype across these 15 families. This powerful approach allowed clinical studies on n ¼ 257 patients with the same mutation, which show that ARVC due to c.1073C.T:p.S358L is particularly lethal. 6 The question remains as to whether other variations in TMEM43, particularly other missense mutations, cause arrhythmic cardiomyopathy in other populations.
Methods

Patient samples
We recruited 143 probands (from 143 families with diagnosed ARVC) from The Heart Hospital, University College London Hospitals, UK. 
Control samples
Two UK population control panels [DNA panels HRC-1 (n ¼ 96) and HRC-2 (n ¼ 96), European Collection of Cell Cultures] were used as ethnically matched controls for the UK patient samples. Newfoundland population-based controls (n ¼ 161) were obtained through random phone dialling, as part of a large colorectal cancer study.
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Genetic studies within families
Genomic DNA was subjected to full gene re-sequencing of TMEM43 as previously described 6 and the ethnically matched controls tested for variants of interest (primer sequences and conditions available upon request). DNA sequences were analysed and variants identified. Variant analysis was carried out using the Mutation Surveyor v3.25 software (SoftGenetics, LLC, PA, USA). For validation purposes, variants were considered pathogenic if they were (i) rare (allele frequency ,1%), (ii) coding (missense, non-sense, or splicing defect), (iii) evolutionarily conserved, 10 -13 (iv) located within a functionally important protein domain, and (v) co-segregated with the disease in multiplex families. Segregation analysis could only be done if DNA samples and clinical assessments were available from other affected relatives.
Bioinformatics tools
We utilized the following bioinformatics tools for pathogenicity analysis: ARVD/C Genetic Variants Database, ClustalW, Online Mendelian Inheritance in Man (OMIM), PANTHER, PolyPhen, SIFT, dbSNP, Splice Site Prediction, SplicePort, and SUMOylation site predictor. When applicable, default parameters were used.
Genetic studies between populations
To identify which recurrent mutations were due to potential founder effects, comparison of the ARVC-haplotypes was carried out. DNA from Newfoundland probands was genotyped for five microsatellite markers spanning TMEM43 on chromosome 3p25, and disease haplotypes inferred by comparing alleles in UK probands to those residing on the disease haplotypes in Newfoundland patients with the same mutation.
Results
Bidirectional sequencing of TMEM43 in UK probands
Bidirectional Sanger sequencing revealed 33 variants in TMEM43 from 143 UK probands. Of these 33 variants, 15 could be ignored because they were previously identified in Newfoundland population controls. 6 Nine of these 15 variants are categorized as having no known pathogenicity in the ARVD/C database. Our data support this classification and we suggest that the remaining six variants should be listed as 'no known pathogenicity' ( Table 1) .
Frequency of TMEM43 variants in UK ARVC probands
Of the 18 variants remaining from the original 33 identified in UK probands and not seen in the Newfoundland controls, five were present in .1% of the UK population control panels and therefore classified as 'no known pathogenicity' ( Family studies of ARVC probands with rare TMEM43 mutations
In the case of an autosomal dominant disease, one of the most convincing arguments for causality is to demonstrate co-segregation between mutation and disease in one or more multiplex families. This is often difficult in a clinical setting, particularly with a lethal disorder such as ARVC, where early expression of the disease is often concealed, and where the first presentation may be with death. 14, 15 We detected the TMEM43 p.R28W variant in one proband ( Figure 1A and C, Individual B1) diagnosed with ARVC following a major syncopal episode. This p.R28W variant was also absent in 380 population control alleles ( Table 2 ), but reported in one of 76 control alleles in dbSNP (in a female of unknown disease status).
The TMEM43 c.424G.A: p.E142K variant was found in two unrelated UK patients ( Figure 1B and D) and one population control sample ( Table 2) , which was homozygous. This is a novel variant and is an evolutionarily conserved amino acid residue.
The TMEM43 c.934C.T: p.R312W variant has been reported in 4/500 control alleles in the ARVD/C database. We detected this missense variant in three clinically affected UK probands from three unrelated families (Figure 2A and B). One family member from UK-1, (individual B1 from whom we have no DNA) died suddenly due to an unspecified 'cardiac arrhythmia' at 37 years of age ( Figure 2B ). Clinical follow-up of his relatives revealed a six-generation family with three cases of young, sudden, unexplained deaths. Subsequently, one first cousin, individual B12, was diagnosed with ARVC 4 and was shown to have one copy of the p.R312W allele ( Figure 3 ). Five additional relatives presenting clinical symptoms of ARVC (individuals A1, B3, B5, B10, and B14) were also identified. DNA was available from individuals B3, B5, and B10, which showed them to be heterozygous for p.R312W. The proband's first cousin, individual B7, has no clinical signs of ARVC and does not have the p.R312W variant. Family UK-2 ( Figure 2B ) was ascertained following the death of a 17 year old (individual A1, DNA unavailable). Subsequent clinical and molecular screening revealed that individual A2, the proband's sibling, fulfilled diagnostic criteria for ARVC and carried the p.R312W variant. Individual B1, the proband of family UK-3, was clinically diagnosed with ARVC following a syncopal event, and was also found to carry the p.R312W variant ( Figure 3B ). The clinical features of these families can be found in greater detail in Table 3 .
Evidence of a second founder mutation (p.R312W) in TMEM43
Two Newfoundland probands (Families NL0186, NL1326; Figure 4 ) were identified as carriers of the TMEM43 p.R312W variant. These p.R312W carriers were genotyped for markers on 3p25 and the alleles compared with p.R312W carriers from the UK (Figure 4 . .... ..... ..... ..... .... ..... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... ..... .... ..... ..... Newfoundland probands share all disease-associated alleles ( Figure 4 ) with UK patients, suggesting that p.R312W resides on a shared ancestral chromosome and giving evidence that p.R312W is a disease-causing founder mutation.
Discussion
The purpose of this study was to investigate if mutations in the TMEM43 cause ARVC or arrhythmogenic cardiomyopathies outside of the genetically isolated population of Newfoundland. Genomic variants are rapidly being identified in public and private laboratories around the world. The ability to determine clinically relevant mutations is essential if we are to understand their genetic contribution to disease and provide predictive and diagnostic value. This is especially critical in the case of cardiac arrhythmias where the first symptom may be death.
The ARVD/C Genetics Variants Database (www.arvcdatabase. info) was recently established to provide a public repository for variants in genes that cause ARVC in order to assist with genotype -phenotype correlations and help determine pathogenicity. 16 It is important to note that, in some instances, the variants reported in the ARVD/C database have been identified in patients with unknown ARVC clinical features and therefore cannot be classified. To date, 53 TMEM43 variants in patients have been reported in the ARVD/C database (accessed 4 September 2012). The p.S358L variant is categorized as pathogenic with an associated disease (ARVC). 6 Another variant (c.705+7G.A), which is listed in the ARVD/C Genetics Variants Database, is considered pathogenic as it showed reduced immuno-reactivity for plakoglobin 16 and has been associated with one ARVC patient. 17 Allele frequency can also serve as a reliable predictor of deleterious amino acid substitutions. For example, in a recent study more than half of the non-synonymous SNPs with an allele frequency of ,1% were shown to be mildly deleterious. 18 We expect an autosomal dominant mutation with the potential to cause a lethal condition in young adults to be relatively infrequent, but not necessarily absent, in ethnically matched controls. For example, in the ARVC extended families, many females live a normal lifespan. 6 In silico programmes can also help predict pathogenicity in the absence of functional assays, which are not available for most diseases, including ARVC.
In the case of an autosomal dominant disease, one of the most convincing arguments for causality is to demonstrate co-segregation between mutation and disease in one or more multiplex families. The TMEM43 c.82C.T: p.R28W variant was detected in ARVC-affected UK individual B1 ( Figure 1A and C ) . B1 has two first-degree relatives (individuals C1 and C4) who both died suddenly at 32 and 33 years of age, respectively, of unknown causes. Our data suggest that p.R28W is rare as it was absent in 380 population control alleles ( Table 2) , although it has been reported in one of 76 control alleles in dbSNP. At the protein level, the p.R28 residue resides in the nucleoplasm, in the vicinity of the first transmembrane domain (Figure 2) , and is conserved from Homo sapiens to the bacterium Rhizobium loti, with one exception being the invertebrate Drosophila melanogaster. The substitution of an arginine for a tryptophan at position 28 is predicted to be deleterious by in silico analysis ( Table 2 ). The arginine residue resides in the hydrophilic region of the N-terminal that, along with the first transmembrane domain, is required for oligomerization. 19 Tryptophan is the most hydrophobic residue, whereas arginine is hydrophilic, 20 hence tryptophan would likely bury itself in the adjacent lipid bilayer and distort the structure or hide other functional residues in the N-terminus. The TMEM43 c.82C.T: p.R28W variant is currently classified as 'No Known Pathogenicity' in the ARVD/C database, with a note stating: 'did not segregate with the disease in a family with a proband who died of SCD at age 25 and was diagnosed with ARVC post-mortem'. However, this result is yet unpublished and there is no clinical or molecular data available for comparison with the families in our study. We suggest that more segregation studies be pursued to further characterize the p.R312W variant. 16, 21 A second novel variant, TMEM43 p.E142K, was found in two unrelated UK patients ( Figure 1B and D) . Residue 142 of TMEM43 is in a predicted SUMO [Small Ubiquitin-related Modifier (SUMO)-ylation] site ( Figure 2 ) in a part of the protein that would normally be unfolded in the endoplasmic reticulum, and is also important for protein stabilization and localization. 6, 10, 22, 23 In silico prediction models suggest that p.E142K is deleterious, though the fact that a control sample was homozygous argues against this prediction. The TMEM43 p.R312W variant was detected in three clinically affected UK patients ( Figure 3 ) who tested negative for p.S358L. Haplotypes of the probands and their families harbouring p.R312W were constructed from microsatellite markers and SNPs that span 1.8 Mb (Figure 4) . In addition to evidence of co-segregation of p.R312W with ARVC in three multiplex UK families, and a shared disease-associated haplotype between patients from the UK and Newfoundland, there is supporting evidence for causation at the protein level. The arginine residue at position 312 (p.R312) is highly conserved and located within a transmembrane domain of TMEM43 (Figure 2) . In silico analyses 24 -26 predict a substitution for tryptophan at position 312 to be deleterious ( Table 2) . Although arginine and tryptophan both play a role in anchoring transmembrane helices at the bilayer interface, 27, 28 tryptophan would likely be located several angstroms closer to the centre of the bilayer compared with arginine, 29 potentially disrupting normal helix -helix interactions. The transmembrane domains of TMEM43 are thought to target the protein to the inner nuclear membrane, 19 and therefore, amino acid substitutions in these highly conserved domains may disrupt the localization of TMEM43 within the nucleus of the cell. We find p.R312W to be a relatively rare, deleterious missense mutation that co-segregates with ARVC in multiplex UK families and conclude a likely pathogenic role for the p.R312W mutation in TMEM43. Whether this variant is causative, or one that influences disease expression alongside an, as yet unknown, epistatic mutation will require more in-depth family studies. Of interest is that in B10 and B12 in UK-1, and in A2 and B2 in family UK-2 PRWP is seen, alongside other evidence of LV anomalies which are major aspects of the phenotype in the Newfoundland p.S358L kindreds and may relate directly to TMEM43. Despite the fact that the p.R312W variant was present in 2.8% of the NL controls and 0.8% of the UK population controls, taken together the evidence suggests that p.R312W is pathogenic. The discovery that two Newfoundland probands with the TMEM43 p.R312W mutation also share the same ARVC-associated haplotype with affected UK family members suggests that the p.R312W allele represents a second founder mutation causing an arrhythmogenic cardiomyopathy in TMEM43. Interestingly, although the families used to define the Newfoundland p.S358L founder mutation are of English ancestry, the p.S358L mutation was not identified in this cohort. 
